EP2344487A4 - Hepatitis c inhibitor compounds - Google Patents
Hepatitis c inhibitor compoundsInfo
- Publication number
- EP2344487A4 EP2344487A4 EP09815517A EP09815517A EP2344487A4 EP 2344487 A4 EP2344487 A4 EP 2344487A4 EP 09815517 A EP09815517 A EP 09815517A EP 09815517 A EP09815517 A EP 09815517A EP 2344487 A4 EP2344487 A4 EP 2344487A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hepatitis
- inhibitor compounds
- inhibitor
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9929208P | 2008-09-23 | 2008-09-23 | |
US18663209P | 2009-06-12 | 2009-06-12 | |
PCT/CA2009/001237 WO2010034105A1 (en) | 2008-09-23 | 2009-09-14 | Hepatitis c inhibitor compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2344487A1 EP2344487A1 (en) | 2011-07-20 |
EP2344487A4 true EP2344487A4 (en) | 2012-03-21 |
Family
ID=42059237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09815517A Withdrawn EP2344487A4 (en) | 2008-09-23 | 2009-09-14 | Hepatitis c inhibitor compounds |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2344487A4 (en) |
JP (1) | JP2012502925A (en) |
AR (1) | AR073659A1 (en) |
CA (1) | CA2737958A1 (en) |
TW (1) | TW201016694A (en) |
WO (1) | WO2010034105A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32099A (en) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS |
KR20110075019A (en) * | 2008-10-15 | 2011-07-05 | 인터뮨, 인크. | Therapeutic antiviral peptides |
SG191759A1 (en) | 2010-12-30 | 2013-08-30 | Enanta Pharm Inc | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | Macrocyclic hepatitis c serine protease inhibitors |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
SG11201502802PA (en) | 2012-10-19 | 2015-05-28 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
DK1654261T3 (en) * | 2003-05-21 | 2008-01-14 | Boehringer Ingelheim Int | Hepatitis C inhibitor compounds |
WO2005116054A1 (en) * | 2004-05-25 | 2005-12-08 | Boehringer Ingelheim International, Gmbh | Process for preparing acyclic hcv protease inhibitors |
CA2556669C (en) * | 2004-06-28 | 2012-05-01 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
MX2009013830A (en) * | 2007-06-29 | 2010-03-01 | Gilead Sciences Inc | Antiviral compounds. |
CN101790524B (en) * | 2007-06-29 | 2014-07-16 | 吉里德科学公司 | Antiviral compounds |
WO2009076173A2 (en) * | 2007-12-05 | 2009-06-18 | Enanta Pharmaceuticals, Inc. | Fluorinated tripeptide hcv serine protease inhibitors |
-
2009
- 2009-09-14 WO PCT/CA2009/001237 patent/WO2010034105A1/en active Application Filing
- 2009-09-14 JP JP2011527161A patent/JP2012502925A/en active Pending
- 2009-09-14 CA CA2737958A patent/CA2737958A1/en not_active Abandoned
- 2009-09-14 EP EP09815517A patent/EP2344487A4/en not_active Withdrawn
- 2009-09-22 TW TW098131961A patent/TW201016694A/en unknown
- 2009-09-22 AR ARP090103651A patent/AR073659A1/en unknown
Non-Patent Citations (2)
Title |
---|
No further relevant documents disclosed * |
See also references of WO2010034105A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2737958A1 (en) | 2010-04-01 |
WO2010034105A8 (en) | 2011-01-06 |
EP2344487A1 (en) | 2011-07-20 |
WO2010034105A1 (en) | 2010-04-01 |
AR073659A1 (en) | 2010-11-24 |
JP2012502925A (en) | 2012-02-02 |
TW201016694A (en) | 2010-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2528926A4 (en) | Hepatitis c inhibitor compounds | |
EP2344487A4 (en) | Hepatitis c inhibitor compounds | |
HK1143812A1 (en) | Hepatitis c virus inhibitors | |
IL207470A0 (en) | Hepatitis c virus inhibitors | |
GB0807862D0 (en) | Compounds | |
EP2504343A4 (en) | Hepatitis c inhibitor compounds | |
GB0800035D0 (en) | Compounds | |
IL213464A0 (en) | Kinase inhibitor compounds | |
GB0804702D0 (en) | Compounds | |
GB0807103D0 (en) | Compounds | |
GB0800367D0 (en) | Compounds | |
GB0807910D0 (en) | Compounds | |
GB0801220D0 (en) | Compounds | |
GB0814990D0 (en) | Compounds | |
GB0801265D0 (en) | Compounds | |
GB0800841D0 (en) | Compounds | |
GB0803496D0 (en) | Compounds | |
GB0800455D0 (en) | Compounds | |
GB0800338D0 (en) | Compounds | |
GB0801219D0 (en) | Compounds | |
GB0817481D0 (en) | Compounds | |
GB0812622D0 (en) | Compounds | |
GB0801596D0 (en) | Compounds | |
GB0802191D0 (en) | Compounds | |
GB0802192D0 (en) | Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110426 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120217 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 31/14 20060101ALI20120213BHEP Ipc: A61K 31/506 20060101ALI20120213BHEP Ipc: A61K 31/4709 20060101ALI20120213BHEP Ipc: C07D 417/14 20060101AFI20120213BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120918 |